Gene-Editing Tops Priority for 54% of Biotech Labs

According to recent data, 54% of advanced biotech laboratories have identified gene-editing research as their main growth engine this year, highlighting the increasing importance of this sector. The worldwide gene therapy market had a valuation of US$ 9.42 billion in 2024 and is anticipated to reach US$ 42.26 billion by 2033, with a compound annual growth rate (CAGR) of 18.15% throughout the forecast period from 2025 to 2033.

Currently, the gene therapy market is poised for remarkable progress, merging scientific innovations with active partnerships in the industry. Simultaneously, 38% of new therapies entering late-stage clinical trials currently include targeted genetic strategies to tackle hereditary conditions that were previously considered untreatable.

Significantly, 42% of newly created partnerships between major pharmaceutical companies and specialized start-ups emphasize the push to hasten innovative trials and simplify approvals. This collaboration has sparked the exchange of ideas between educational institutions and business organizations, as 64% of top pharmaceutical firms are adjusting their 2023 investment plans to include a wider range of gene therapy opportunities. These daring actions create an encouraging image of a market ready to transform the foundation of contemporary medicine.

A notably remarkable trend is the shift in research and development funding within the gene therapy sector, where 36% of R&D investments for gene therapy are currently dedicated solely to next-generation delivery methods, such as lipid nanoparticles and innovative viral vectors. A 2023 survey reveals that 59% of regulatory agencies globally have revised their frameworks to speed up approvals for gene therapies for orphan or life-threatening conditions, triggering a surge in market activity.